These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

589 related items for PubMed ID: 7847036

  • 21. Efficacy of prothrombin-complex concentrates in hemophiliacs with antibodies to factor VIII: a multicenter therapeutic trial.
    Lusher JM, Shapiro SS, Palascak JE, Rao AV, Levine PH, Blatt PM.
    N Engl J Med; 1980 Aug 21; 303(8):421-5. PubMed ID: 6771653
    [Abstract] [Full Text] [Related]

  • 22. Use of prothrombin complex concentrates in hemophiliacs with inhibitors: clinical and laboratory studies.
    Buchanan GR, Kevy SV.
    Pediatrics; 1978 Nov 21; 62(5):767-74. PubMed ID: 724319
    [Abstract] [Full Text] [Related]

  • 23. Inhibitors in young boys with haemophilia.
    Lusher JM.
    Baillieres Best Pract Res Clin Haematol; 2000 Sep 21; 13(3):457-68. PubMed ID: 11030045
    [Abstract] [Full Text] [Related]

  • 24. A higher than expected incidence of factor VIII inhibitors in multitransfused haemophilia A patients treated with an intermediate purity pasteurized factor VIII concentrate.
    Peerlinck K, Arnout J, Gilles JG, Saint-Remy JM, Vermylen J.
    Thromb Haemost; 1993 Feb 01; 69(2):115-8. PubMed ID: 8456422
    [Abstract] [Full Text] [Related]

  • 25. Use of porcine factor VIII in the management of seventeen patients with factor VIII antibodies.
    Gatti L, Mannucci PM.
    Thromb Haemost; 1984 Jul 29; 51(3):379-84. PubMed ID: 6437005
    [Abstract] [Full Text] [Related]

  • 26. [Postpartum hemophilia A with factor VIII inhibitor].
    Neidhardt B, Bartels O, Hahn B.
    Dtsch Med Wochenschr; 1985 May 17; 110(20):799-802. PubMed ID: 3922727
    [Abstract] [Full Text] [Related]

  • 27. The effect of activated prothrombin-complex concentrate (FEIBA) on joint and muscle bleeding in patients with hemophilia A and antibodies to factor VIII. A double-blind clinical trial.
    Sjamsoedin LJ, Heijnen L, Mauser-Bunschoten EP, van Geijlswijk JL, van Houwelingen H, van Asten P, Sixma JJ.
    N Engl J Med; 1981 Sep 24; 305(13):717-21. PubMed ID: 6790990
    [Abstract] [Full Text] [Related]

  • 28. [Acquired hemophilia caused by autoantibodies against factor VIII coagulation activity. Clinical, biological study and therapeutic indications. Experience based on a study of 9 cases].
    Liozon E, Delaire L, Turlure P, Jaccard A, Loustaud-Ratti V, Réméniéras L, Julia A, Gaillard S, Bordessoule D, Vidal E.
    Ann Med Interne (Paris); 1997 Sep 24; 148(7):477-90. PubMed ID: 9538386
    [Abstract] [Full Text] [Related]

  • 29. Prevalence of the intron 22 inversion of the factor VIII gene and inhibitor development in Polish patients with severe hemophilia A.
    Sawecka J, Skulimowska J, Windyga J, Lopaciuk S, Kościelak J.
    Arch Immunol Ther Exp (Warsz); 2005 Sep 24; 53(4):352-6. PubMed ID: 16088320
    [Abstract] [Full Text] [Related]

  • 30. Acquired hemophilia.
    Bouvry P, Recloux P.
    Haematologica; 1994 Sep 24; 79(6):550-6. PubMed ID: 7896216
    [Abstract] [Full Text] [Related]

  • 31. Inhibitor to factor VIII in mild haemophilia.
    Kesteven PJ, Holland LJ, Lawrie AS, Savidge GF.
    Thromb Haemost; 1984 Aug 31; 52(1):50-2. PubMed ID: 6437010
    [Abstract] [Full Text] [Related]

  • 32. Recent advances in hemophilia.
    Tann G.
    Southeast Asian J Trop Med Public Health; 1979 Jun 31; 10(2):218-28. PubMed ID: 524146
    [Abstract] [Full Text] [Related]

  • 33. Prevalence of IgG antibodies to human parvovirus B19 in haemophilia children treated with recombinant factor (F)VIII only or with at least one plasma-derived FVIII or FIX concentrate: results from the French haemophilia cohort.
    Gaboulaud V, Parquet A, Tahiri C, Claeyssens S, Potard V, Faradji A, Peynet J, Costagliola D, Suivi Thérapeutique National des Hémophiles Group.
    Br J Haematol; 2002 Feb 31; 116(2):383-9. PubMed ID: 11841442
    [Abstract] [Full Text] [Related]

  • 34. The management of factor VIII inhibitors in non-hemophilic patients.
    Green D.
    Prog Clin Biol Res; 1984 Feb 31; 150():337-52. PubMed ID: 6431438
    [Abstract] [Full Text] [Related]

  • 35. [Prothrombin complex concentrates in the treatment of hemorrhage in a non-hemophilic patient with a high factor VIII inhibitor level].
    Tsuji K, Takasugi Y, Kumei Y, Namiki M, Kubota K.
    Rinsho Ketsueki; 1987 Jul 31; 28(7):1187-93. PubMed ID: 3121896
    [No Abstract] [Full Text] [Related]

  • 36. [Treatment of patients with hemophilia A having antibodies to factor VIII].
    Lopaciuk S, Ziemski JM.
    Acta Haematol Pol; 1979 Jul 31; 10(2):115-22. PubMed ID: 474044
    [Abstract] [Full Text] [Related]

  • 37. [Comparison of anti-human and anti-porcine factor VIII antibody titers in patients with hemophilia].
    Windyga J, Rzymkiewicz L, Lopaciuk S.
    Acta Haematol Pol; 1996 Jul 31; 27(1):27-31. PubMed ID: 8629440
    [Abstract] [Full Text] [Related]

  • 38. Strategies to promote hemostasis in patients with F VIII inhibitors.
    Lusher JM.
    Prog Clin Biol Res; 1990 Jul 31; 324():39-46. PubMed ID: 2106691
    [No Abstract] [Full Text] [Related]

  • 39. Disappearance of factor VIII antibodies upon frequent administration of factor VIII.
    Mauser-Bunschoten EP, Roosendaal G, Bruin M, van Dijken PJ.
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1990 Jul 31; 117(4):533-7. PubMed ID: 1714856
    [Abstract] [Full Text] [Related]

  • 40. [Hemophiliacs with inhibitor. Experience at the Center of Medical Action for Hemophilia of the S. José Hospital].
    Diniz MJ, Dias Francisco F, Tavares ML, Leal I.
    Acta Med Port; 1992 Apr 31; 5(4):178-80. PubMed ID: 1605065
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 30.